Passion for Leading Technology Advancement Towards Transformative Solutions
Our Harbour Mice® antibody technology platforms are supported by our comprehensive suite of in-house technology tools, including single B cell cloning, Next Generation Sequencing, immunizations, bioinformatics, protein science, yeast/phage/mammalian display library and antibody engineering only highlight most important ones. For example, combining single B cell cloning technology with Harbour Mice®, we have shortened time from target to high quality lead mAb candidates with exceptional biophysical properties to approximately four months, vs. the industry average of nine months. The fully human antibody panel from Harbour Mice® further saves time and complexity of the humanization process, thereby provides significant flexibility and choice of candidates to improve druggability properties for CMC and clinical development. We are one of the leading biotech companies in the world capable of integrating single B cell high throughput screening and fully human antibody transgenic mouse platform. This allows us to significantly increase efficiency and reduce overall costs.
Moreover, with our HBICE® bispecific technology, we can generate flexible corresponding formats to accommodate the different biology mode of actions. The mammalian direct cloning platform enables us to highly efficiently screen bispecific antibodies than traditional approaches.
We own exclusive global rights to use and develop our Harbour antibody platforms, which are protected by global patents and rights, enabling us to maximize the value of our platforms to address global unmet medical needs.
Furthermore, we have established a strong track record of success for our H2L2 Platform, which has been highly validated by over 46 industry and academic partners with 6 projects having entered into Phase 1 clinical trials as of June 30, 2020.
These achievements are testaments to our discovery team’s acumen and technical prowess in translating target biology into points of innovation or differentiation. Driven by an experienced group of over 100 scientists - with extensive research and drug development experience, our operation in the United States, the Netherlands and China is advancing our mission:
To Be the Leading Company Driving Global Innovation of NextGen Antibody Therapeutics.
Transgenic mice have emerged as powerful tools for use in biologic drug discovery based on their potential for producing fully human antibodies. The majority of fully human antibodies approved to date in the U.S. have emerged from one or the other transgenic mice platform.
Transgenic mice have emerged as powerful tools for use in biologic drug discovery based on their unique potential in producing fully human antibodies. The platforms have broad potential for generating both conventional antibody therapeutics as well as the Next-Gen biologics that are affinity matured, fully human with excellent solubility and developability.
Single Cell Technology Platform
The single cell technology has been widely used in biomedical research. We acquired Berkeley lights’ advanced Beacon® Optofluidic technology and established our single cell technology platform currently focusing on single B cell cloning to enhance our fully human antibody discovery capability and single cell analysis for translational cancer research.view more
Harbour HCAb platform can generate diverse and stable fully human Heavy Chain only Antibodies (HCAbs) and derived human VH single-domain moieties, enabling us to make novel multi-specific and multi-valent antibodies in simplified structures with relatively smaller molecule size and fewer number of polypeptide chains. On top of this, we have established proprietary HBICE® (HCAb Based Immune Cell Engagers) platform to quickly develop multi-specific antibodies which redirect immune cells to the tumor microenvironment (TME) to eradicate tumors.view more